The FDA has approved Inlexzo (gemcitabine intravesical system) for the treatment of adult patients with BCG-unresponsive, non-muscle invasive bladder cancer with CIS with or without papillary tumors.

Beyond GLP-1 RA prescriptions, chronic kidney disease (CKD) patients require comprehensive care from doctors, dietitians, & ...

Multiparametric MRI was a game changer for prostate cancer diagnosis. Now trial findings suggest a simpler imaging protocol may be as effective.

An investigational factor XI inhibitor shows early promise for treating atrial fibrillation in patients with a degree of kidney impairment.

However, BCC rates similar by College of American Pathologists and Clinical and Laboratory Standards Institute criteria.

(HealthDay News) — Poor cardiovascular-kidney-metabolic (CKM) health is associated with an increased risk for psoriasis, especially for those with high genetic risk, according to a study published ...

The committee found strong evidence that glucagon-like peptide-1 (GLP-1) receptor agonists benefit people with type 2 diabetes, particularly those with heart or kidney disease, by improving glucose ...

As changes to Medicare Part D prescription drug coverage have taken effect with implementation of the IRA, concurrent changes in plan design have increased cost-sharing burdens for patients, data ...

Study findings support intensive blood pressure control in patients with hypertension without chronic kidney disease at baseline.

Oral semaglutide was linked to reduced SU levels among patients with T2D, particularly among individuals with hyperuricemia and those who switched from a DPP-4 inhibitor.

Investigators compared survival among patients with limited-stage small cell bladder cancer receiving different treatment approaches.

Patients with cancer may have medical debt in collections that persists for years after their diagnosis, despite high rates of insurance coverage.